HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Put DHEA Under DEA, Amend DSHEA, Waxman Says At Andro Bill Markup

This article was originally published in The Tan Sheet

Executive Summary

Dehydroepiandrosterone's exemption from the controlled substances list in the Anabolic Steroid Control Act of 2004 is likely to be challenged when the bill moves to the House floor

You may also be interested in...

Steroid Bill Clears House Judiciary Committee; Senate Floor Next?

As promised by Capitol Hill sponsors, the Anabolic Steroid Control Act is moving relatively quickly through both chambers of Congress

DHEA Controlled Substance Status Sought By Sweeney Under Andro Bill

Exemption of dehydroepiandrosterone (DHEA) from a ban of steroid precursors looks to be the main point of disagreement facing the Anabolic Steroid Control Act of 2004 when the bill heads for conference

House Bill Prohibits Sale Of High-Risk Supplements To Minors

Consumers under age 18 would not be allowed to purchase dietary supplements that FDA deems as posing a significant risk to minors, according to a new bill authored by Rep. Susan Davis (D-Calif.)

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts